LIGIA FLORIO

(Fonte: Lattes)
Índice h a partir de 2011
2
Projetos de Pesquisa
Unidades Organizacionais

Resultados de Busca

Agora exibindo 1 - 4 de 4
  • conferenceObject
    DIMENSIONAL INVESTIGATION OF FOOD ADDICTION IN INDIVIDUALS WHO HAVE UNDERGONE BARIATRIC SURGERY
    (2023) FLORIO, Ligia; CASTALDELLI-MAIA, Joao Mauricio
  • article 5 Citação(ões) na Scopus
    Food Addiction A Comprehensive Review
    (2022) FLORIO, Ligia; LASSI, Dangela L. S.; PERICO, Cintia De Azevedo-Marques; VIGNOLI, Natalia G.; TORALES, Julio; VENTRIGLIO, Antonio; CASTALDELLI-MAIA, Joao M.
    Food addiction is associated with dysfunctions in the reward circuit, such as hyperresponsiveness during the exposure to high-calorie flavors in overweight and obese individuals. Similar to drug addiction, there is also impaired self-regulatory control supported by deregulation of the frontostriatal circuit. The inclusion of validated measures of food addiction in clinical research, such as the Yale Food Addiction Scale, has increased the understanding of the clinical utility of this concept. Furthermore, food addiction, eating disorders, and obesity are interrelated. Thus, it is important to recognize food addiction among individuals affected by obesity and candidates for bariatric surgery (ie, preoperative and postoperative assessment). In this context, it has been reported that food addiction may impede weight loss and increase the likelihood of regaining weight when associated with personality traits such as neuroticism and impulsiveness, which are also related to mood disorders, anxiety, and addictive behaviors.
  • article 12 Citação(ões) na Scopus
    Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review
    (2022) LASSI, Dangela Layne Silva; MALBERGIER, Andre; NEGRAO, Andre Brooking; FLORIO, Ligia; AQUINO, Joao P. De; CASTALDELLI-MAIA, Joao Mauricio
    Background: cocaine craving is a core feature of cocaine use disorder and remains a critical challenge for abstinence and relapse prevention. This review summarizes the anti-craving efficacy of pharmacotherapies tested for cocaine use disorder, in the context of randomized-controlled clinical trials. Objectives: we assessed the databases of the U.S. National Library of Medicine, Google Scholar, and PsycINFO, without date restrictions up to August 2022, to identify relevant studies. Study eligibility criteria, participants, and interventions: we included double-blinded randomized-controlled trials investigating pharmacotherapies for cocaine craving and/or cocaine use disorder whose outcomes included cocaine craving. Study appraisal and synthesis methods: Two authors screened studies' titles and abstracts for inclusion, and both read all the included studies. We systematically gathered information on the following aspects of each study: title; author(s); year of publication; sample size; mean age; sample characteristics; study set-ting; whether participants were treatment-seeking; study design; craving measures; study interventions; drop-out rates; and other relevant outcomes. Results: Overall, we appraised 130 clinical trials, including 8137 participants. We further considered the drugs from the studies that scored equal to or greater than six points in the quality assessment. There was a correlation between craving and cocaine use outcomes (self-reports, timeline follow-back or urinary benzoylecgonine) in the vast majority of studies. In the short-term treatment, acute phenylalanine-tyrosine depletion, clonidine, fenfluramine, meta-chlorophenylpiperazine (m-CPP) and mecamylamine presented promising effects. In the long term, amphetamine, biperiden, carbamazepine, lisdexamfetamine, lorcaserin, methamphetamine, mirtazapine, pioglitazone, progesterone, guanfacine, levodopa, nefazodone presented promising anti-craving effects. Unfortunately, the highly tested medications were not successful in most of the trials, as follows: propranolol in the short term; amantadine, aripiprazole, bromocriptine, citicoline, ketamine, modafinil, olanzapine, topiramate in the long term. The remaining 52 medications had no positive anti-craving outcomes. Limitations: Our review was limited by high heterogeneity of craving assessments across the studies and by a great range of pharmacotherapies. Further, the majority of the studies considered abstinence and retention in treatment as the main outcomes, whereas craving was a secondary outcome and some of the studies evaluated patients with cocaine use disorder with comorbidities such as opioid or alcohol use disorder, schizophrenia, bipolar disorder or attention deficit hyperactivity. Lastly, most of the studies also included non-pharmacological treatments, such as counseling or psychotherapy. Conclusions: There is a direct association between craving and cocaine use, underscoring craving as an important treatment target for promoting abstinence among persons with cocaine use disorder. Clonidine, fenfluramine and m-CPP showed to be promising medications for cocaine craving in the short-term treatment, and amphetamine, biperiden, carbamazepine, lisdexamfetamine, lorcaserin, methamphetamine, mirtazapine, pioglitazone, progesterone, guanfacine, levodopa, nefazodone in the long-term treatment.
  • article 0 Citação(ões) na Scopus
    Understanding food addiction in Post-Bariatric patients
    (2023) FLORIO, Ligia; PERICO, Cintia de Azevedo-Marques; CASTALDELLI-MAIA, Joao Mauricio
    This study delves into the construct validity of Food Addiction (FA) as evaluated by the modified Yale Food Addiction Scale 2.0 (mYFAS 2.0) within the context of post-bariatric surgery patients in Brazil. Understanding the prevalence, characteristics, and construct validity of FA among individuals who have undergone bariatric surgery is crucial for enhancing patient care and advancing research in this field. Our findings are based on a convenience-based sample of 100 individuals who had undergone bariatric surgery at Hospital Estadual Mario Covas (HEMC) in Brazil. Using mYFAS 2.0, we found that 51% of the participants met the criteria for FA, with 31% classified as severely affected. In our investigation of construct validity, we confirmed a one-dimensional model, in line with prior research using the YFAS and its modified versions. Item Response Theory (IRT) analyses further confirmed the appropriateness of the mYFAS 2.0 items, with all criteria contributing to the latent structure, most exhibiting discrimination values exceeding 0.5, and the majority having values greater than 2. These results provide substantial support for the construct validity of mYFAS 2.0 in our Brazilian subpopulation of post-bariatric surgery patients. Comparative analyses with previous studies revealed a notably higher prevalence of FA in our population, suggesting potential differences between pre- and post-bariatric surgery groups. This study contributes unique insights into the assessment of FA among post-surgery patients and highlights the importance of early detection and intervention in this population. While this study advances our understanding of FA in post-bariatric surgery patients, certain limitations, such as the relatively small sample size and cross-sectional design, warrant consideration. Nevertheless, our findings hold valuable implications for healthcare providers, researchers, and patients in the field of bariatric surgery and FA management. Future research can build upon these foundations to explore long-term FA effects post-surgery and potential interventions to address this issue effectively.